FORMULATION DEVELOPMENT AND EVALUATION OF ALLOPURINOL SOLID DISPERSIONS BY SOLVENT EVAPORATION TECHNIQUE
Objective: The main objective of the research work is to develop and characterize allopurinol (ALPN) solid dispersions with different polymers to enhance solubility, enrich dissolution profile and improve patient compliance.
Methods: ALPN solid dispersions were prepared by solvent evaporation technique using various grades of polyethelene glycol (PEG) such as PEG 4000 and PEG 6000 with different ratios like 1:0.5, 1:1, 1:1.5 and 1:2 and after formation of solid dispersions all physicochemical properties were examined.
Results: All the formulations were found within the permissible pharmacopoeial limits for various physicochemical parameters. The pre-formulation studies, like Fourier, transform infrared spectroscopy (FTIR) showed the absence of drug-excipient interactions. The solubility and dissolution profiles of the sample were increased with increasing the concentration of ALPN solid dispersions. Solvent evaporation was proved to be a successful technique for the development of stable solid dispersion of ALPN. The dissolution amount percentage of ALPN formulations was found between 39.58Â±2.5 to 94.95Â±1.8 % within 60 min.
Conclusion: Hence, from the all evaluation studies, it was evident that F1 formulation was the better formulation. F1 formulation (ALPN: PEG 4000 in the ratio of 1:0.5), 94.95Â±1.8 % drug released within 50 min.
2. Yadav VB, Yadav AV. Liquisolid granulation technique for tablet manufacturing: an overview. J Pharm Res 2009;2:670-4.
3. Clarkâ€™s. Analysis of drugs and poisons in pharmaceutical body fluids and postmartum materials. 3rd ed. London: Pharmaceutical Press; 2004.
4. Benzra SA, Bennett TR. Analytical profiles of drug substances and excipients. Academic Press Inc 1978;7:1-18.
5. Day RO, Grham GG, Hicks M, Mclchlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol. Clin Pharmacokinet 2007;46:623-44.
6. Samy EM, Hassan MA, Tous SS, Rhodes CT. Improvement of availability of allopurinol from pharmaceutical dosage forms I: suppositories. Eur J Pharm Biopharm 2000;49:119-27.
7. Jagdale SC, Kuchekar BS, Chabukswar AR, Musale VP, Jadhao MA. Preparation and in vitro evaluation of allopurinol-gelucire 50/13 solid dispersions. Int J Adv Pharm Sci 2010;1:60-7.
8. Aggarwal S, Gupta GD, Chaudhary S. Solid dispersion as an eminent strategic approach in solubility enhancement of poorly soluble drugs. Int J Pharm Sci Res 2010;1:1-13.
9. Jadi RK, Tatikonda A, Veera Reedy PR, Venisetty R. Design and characterization of pregabalin swellable core osmotic pumps. Int J Pharm Res Allied Sci 2016;5:8-15.
10. Zedong D, Ashish C, Harpreet S, Duk SC, Hitesh C, Navnit S. Evaluation of solid state properties of solid dispersions prepared by hot-melt extrusion and solvent co-precipitation. Int J Pharm 2008;355:141-9.
11. Goldberg AH, Galbaldi M, Kanig KL. Increasing dissolution rates and gastrointestinal absorption of drugs via solid solutions and eutectic mixtures III. Experimental evaluation of griseofulvin-succinic acid solution. J Pharm Sci 1966;55:487-92.
12. Samy EM, Hassan MA, Tous SS, Rhodes CT. Improvement of availability of allopurinol from pharmaceutical dosage forms I: suppositories. Eur J Pharm Biopharm 2000;49:119-27.
13. Ahrabi SF, Madsen G, Dyrstad K, Sande SA, Graffner C. Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur J Pharm Sci 2000;10:43-52.
14. Sangeeta M, Abhisek P. Dissolution enhancement of seroquel by solid dispersion techniques. Asian J Pharm Clin Res 2016;9:284-7.
15. Niamprem P, Srinivas SP, Tiyaboonchai W. Development and characterization of indomethacin-loaded mucoadhesive nanostructured lipid carriers for topical ocular delivery. Int J Appl Pharm 2018;10:91-6.
16. Mura P, Furlanetto S, Cirri M, Maestrelli F, Marras AM, Pinzauti S. Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and d-optimal mixture experimental design. J Pharm Biomed Anal 2005;37:65â€“71.
17. United States Pharmacopeial Convention. USP 31. United States Pharmacopeial Convention; 2007.
18. Costa P, Sousa Lobo JM. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123â€“33.
19. Togaru V, Venisetty RK, Bakshi V, Jadi RK. Formulation development and in vitro evaluation of propranolol hydrochloride extended-release matrix tablets. Emerg L Sci Res 2017;3:38-47.
20. Geetha A, Rajendra Kumar J, Pavani U, Kalyani CH. Design and in vivo characterization of amlodipine besylate orodispersible tablets. J Global Trends Pharma Sci 2017;8:4325-36.
21. Jadi RK, Bomma R, Sellappan V. Development of a new single unit dosage form of propranolol HCl extended-release non-effervescent floating matrix tablets: In vitro and in vivo evaluation. J Appl Pharma Sci 2016;6:112-8.